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Human tissue legislation is complex. It is characterised 
by an ever-changing landscape in which advances 
in science and medicine need to be accommodated. 
A high degree of technical expertise is required to 
ensure that the legislation is accurate, appropriate and unambiguous. 
However, it is generally accepted that the law has struggled to keep 
pace with advances in science and technology.[1]
The legislative framework governing the control and use of human 
tissue has at its apex the Constitution of the Republic of South 
Africa, 1996, relevant statutes and regulations, as well as standards 
and guidelines. The legal force and status of each of these and the 
extent to which they have been developed in South Africa (SA) with 
regard to the regulation of human tissue are summarised in Table 1. 
The development of legislation is preceded by a policy document 
detailing the objectives and expectations of the proposed legislation.
Stem cell research and therapy
Stem cells are defined as undifferentiated cells capable of self-renewal 
that can differentiate into specialised cell types in response to appropriate 
environmental (e.g. chemical, mechanical) cues. There are several types 
of stem cells, which for the purpose of this discussion we will divide into 
pluripotent and adult. Pluripotent stem cells include embryonic stem 
(ES) cells and induced pluripotent stem (iPS) cells, while adult stem cells 
include haematopoietic and mesenchymal stem cells (HSCs and MSCs). 
Most other stem cell types can be included in this broad definition. Pepper, 
Gouveia and Slabbert will deal with pluripotent stem cells in detail in the 
article on pg. 23 of this special issue. A limited number of clinical trials 
involving pluripotent stem cells are underway, in which differentiated 
and specialised derivatives of these cells are being assessed.
With regard to adult stem cells, HSC transplantation is the only 
universally accepted and routinely applied form of stem cell therapy. 
The potential for stem cells to be used in the treatment of a much 
broader spectrum of diseases is real, but hard to measure. This 
includes epidermal cells for skin defects and autologous cartilage 
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Table 1. The legislative framework governing the control and 
use of human tissue






standards No None officially
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implantation for articular cartilage defects. Clinical trials are underway 
to assess the use of stem cells in the treatment of heart disease. 
Likewise, preclinical and early clinical trials have highlighted the 
potential of stem cells for the treatment of diabetes, spinal cord 
injury and other central nervous system disorders (e.g. cerebral 
palsy and Parkinson’s disease). Adult stem cells per se display very 
few complications, while the major potential risk associated with 
pluripotent cells is tumorigenicity.
There are several essential pillars to a successful cell therapy 
environment. These include a robust regulatory environment, quality 
assurance and accreditation. Also essential is an appropriate informed 
consent process, in which the benefits and potential side-effects 
of the therapy are clearly laid out. The legal requirements for tissue 
donation should also be clearly articulated to curtail possible trade 
and trafficking in human tissue.
What is the current situation in SA? Hematopoietic stem cell 
transplantation has been practised successfully in the country for 
several decades. Sources of stem cells mainly include bone marrow and 
peripheral blood, which may be autologous, or allogeneic. Umbilical cord-
blood-derived stem cells have also been used. SA also has a Bone Marrow 
Registry (SABMR)[2] that sources stem cells from unrelated voluntary 
donors for allogeneic transplantation. SA does not at present have a 
public cord-blood stem cell bank. In SA private cord-blood banking is 
offered by Netcells Biosciences and Cryo-Save South Africa. The difference 
between public and private banks is essentially the difference between 
an anonymous donation versus storage for private use: in the case of a 
public bank, cord blood is donated altruistically and is available for any 
histocompatible patient who needs an allogeneic transplant, while in the 
case of a private bank, the bank is paid to store cord-blood stem cells for 
autologous use or for use by next-of-kin. Private banks are contractually 
obliged to return the stored cells on request and at the bank’s expense, 
exclusively to the owner (or a contractually determined beneficiary).
Human tissue legislation – objectives
Human tissue legislation broadly aims to protect the individual from 
harmful and unethical practices, while at the same time giving effect 
to the individual’s right to autonomy and self-determination as this 
relates to decisions regarding the use of his or her own stem cells. 
The Constitution directs in section 39(2) that, when interpreting 
legislation, every court, tribunal or forum ‘must promote the spirit, 
purport or objects of the Bill of Rights’, which in essence refers to 
the promotion of the public interest.  The legislative process should 
strive to further the goals and objectives of the Constitution, which 
includes the promotion of human rights. For example, all South 
Africans should be able to share in the benefits arising from advances 
in medical science in an equitable and sustainable manner.   
In developing legislation, objectives should be realistic and every 
effort should be made to ensure simplicity and clarity. In the context 
of the regulation of human tissue, legislation should be enabling 
and not be unduly restrictive so as to avoid stifling basic and clinical 
research and biotechnological innovation. If legislation includes 
sanctions, these should be unambiguous and legally justified. Those 
affected by any legislative restriction or penalty should be aware of 
the limitations and the consequences of any transgressions. 
In order to achieve all of the above, South African-specific objectives 
need to be combined with international best practice and the 
involvement of local professional societies needs to be encouraged.
The South African Constitution
The Constitution of the Republic of South Africa, 1996, enshrines the 
values on which SA’s constitutional democracy is founded.  Chapter 2 of 
the Constitution (the Bill of Rights) contains the fundamental rights and 
freedoms. These rights may be limited by section 36 of the Constitution 
and are therefore not absolute. However, some of the rights that are 
specifically relevant in the context of the regulation of human tissue are 
the right to equality (section 9); the right to human dignity (section 10); 
the right to life (section 11); the right to privacy (section 14); the right of 
a person to freedom and security, which includes the right to security in 
and control over one’s body and the right not to be subjected to medical 
or scientific experiments without informed consent (section 12); and the 
right of access to healthcare (section 27).
The following four principles, espoused by Beauchamp and 
Childress[3] provide a very useful framework for the consideration of 
medical ethics issues generally, namely: 
• Autonomy, which includes respecting the patient’s right to make 
decisions regarding her or his treatment. In this respect, consent 
always needs to be informed in the broadest sense with the patient 
being made aware of both the benefits and possible side-effects. 
The importance of an adequate Materials Transfer Agreement 
cannot be overemphasised, particularly in a country in which 
discrimination and benefit sharing have not been adequately 
addressed. Both autonomy and self-determination are recognised 
in the provisions regarding the right to bodily and psychological 
integrity, the right to privacy and the right to life. Human dignity, 
inextricably linked to health and life as a constitutional value, 
informs the interpretation of all other rights.[4]
• Beneficence, the moral foundation on which the medical profession 
rests, includes a consideration of the benefits of treatment against 
risks and costs. It is also critical that the therapy being applied has 
previously been shown to be of benefit in patients with a similar 
condition, preferably through the avenue of well-controlled and 
appropriately designed clinical trials. Beneficence finds expression 
in the provisions of the Constitution that relate to the right to life 
and the right of access to healthcare services (within the limits of 
available resources).
• Non-maleficence, which implies avoiding the causation of harm. 
The harm should not be disproportionate to the benefits of the 
treatment. Early phase clinical trials (phases I and II) are required 
to establish the facts. This principle is expressed, for example, in 
the constitutional right not to be subjected to medical or scientific 
experiments without informed consent.
• Justice and fairness, which require that benefits, risks and costs be 
distributed fairly. In the SA context, distributive justice will ensure 
that all South Africans will benefit from cell-based therapy. The 
right to equality and the right of access to healthcare services 
embody these principles.
These four principles are not only aligned with the Constitution, but if 
observed, will promote the realisation of the rights articulated therein, 
in addition to assisting in deterring possible criminal and unprofessional 
conduct in the context of stem cell research and therapy.
The Acts
Principally Chapter 8 of the National Health Act (NHA) 61 of 2003 
governs the legal regulation of human tissues. The NHA has 
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repealed and replaced the Human Tissue Act 65 of 1983, which 
governed many areas of human tissue legislation but was clearly 
lacking with regard to more recent developments in the field. 
Briefly, the National Health Act makes provision in Chapter 8 for 
control of the use of blood, blood products, tissue and gametes 
in humans. This includes provisions regulating, among others, the 
removal and use of tissue, blood, blood products or gametes from 
living persons and the transplantation of tissue from one living 
person to another. The Act also regulates payment in connection 
with the importation, acquisition or supply of tissue, blood, blood 
products or gametes, as well as the donation of human bodies and 
tissue from deceased persons. Chapter 8 furthermore provides for 
the allocation and use of human organs, as well as the purposes 
of the donation of the body, tissue, blood or blood products of 
deceased persons. The post-mortem examination of bodies, 
including the removal of tissue at post-mortem examinations 
and obtaining of tissue by institutions and persons are also 
regulated by the Act. In addition, not only is trade or trafficking 
in the human body or body parts prohibited in terms of section 
60(4), as is the exploitation of the body as a commodity, but such 
conduct would also violate the right to human dignity reflected in 
the Constitution. The Medicines and Related Substances Control 
Act 101 of 1965 (Medicines Act) is more relevant to the clinical 
translation of stem cell therapy than the research component of 
stem cells, while the Children’s Act 38 of 2005, the Inquest Act 58 of 
1959 and the Consumer Protection Act 68 of 2008 all have bearing 
on stem cell research and therapy in SA.
The NHA was assented to by the President on 18 July 2004 and 
came into force on 2 May 2005. However, the main section dealing 
with human tissues, namely Chapter 8 entitled the ‘Control of use 
of blood, blood products, tissue and gametes in humans’, was only 
fully enacted as recently as 2 March 2012. As mentioned previously, 
matters pertaining to human tissues were previously legislated 
under the Human Tissue Act 65 of 1983, which was repealed with the 
enactment of the final sections of the NHA in 2012.[5]
Chapter 8 of the NHA covers seven areas that are relevant to 
human tissues. These include:
• Blood and blood products
• Assisted reproductive technology
• Cell-based therapy
• Transplantation
• DNA and genetic services
• Tissue banks
• Examination, allocation and disposal of human bodies and tissues.
‘Tissue’ is defined in section 1 of the NHA as ‘human tissue, and 
includes flesh, bone, a gland, an organ, skin, bone marrow or body 
fluid, but excludes blood or a gamete’. An organ is defined in the 
same section as ‘any part of the human body adapted by its structure 
to perform any particular vital function, including the eye and its 
accessories’. Suggested alternatives to these definitions are provided 
in Table 2.
With regard to human cloning, the manipulation of any genetic 
material for the purpose of reproductive cloning of a human being 
is prohibited in terms of section 57(1) of the NHA, read together 
with section 57(6)(a).  Cloning for therapeutic purposes is provided 
for in section 57(2) of the Act, read together with section 57(6)(b). 
These definitions (i.e. ‘reproductive cloning of a human being’ and 
‘therapeutic cloning’) are however problematic; alternatives are 
provided in Table 3. A person contravening or failing to comply with 
this section is guilty of an offence and is liable, on conviction, to a fine 
or to imprisonment for a period not exceeding 5 years or to both a 
fine and such imprisonment (section 57(5)).
Research on stem cells and zygotes which are not more than 14 
days old may in terms of section 57(4) of the NHA only be conducted 
with the permission of the Minister and under certain conditions, 
namely that the research shall be documented and prior consent be 
obtained from the donor of such stem cells or zygotes.
Section 56 of the NHA (‘Use of tissue, blood, blood products or 
gametes removed or withdrawn from living persons’) provides that 
that the removal or withdrawal of stem cells (excluding umbilical cord 
progenitor cells) from a living person for medical or dental purposes 
requires ministerial authorisation. Specific restrictions regarding 
the removal of tissue, blood, blood products or gametes from living 
persons are found in section 56(2), which states as follows:
‘(2) (a) Subject to paragraph (b), the following tissue, blood, blood 
products or gametes may not be removed or withdrawn from a living 
person for any purpose contemplated in subsection (1):
(i) tissue, blood, a blood product or a gamete from a person who is 
mentally ill within the meaning of the Mental Health Care Act, 2002 (Act 
no. 17 of 2002);
(ii) tissue which is not replaceable by natural processes from a person 
younger than 18 years;
(iii) a gamete from a person younger than 18 years; or
(iv) placenta, embryonic or foetal tissue, stem cells and umbilical cord, 
excluding umbilical cord progenitor cells.
(b) The Minister may authorise the removal or withdrawal of tissue, 
blood, a blood product or gametes contemplated in paragraph (a) and 
may impose any condition which may be necessary in respect of such 
removal or withdrawal.’
This implies that HSC transplantation, which has been practised 
for several decades in SA, requires ministerial authorisation, as will 
all future applications of stem cell therapy requiring removal or 
withdrawal of stem cells from a living person. The exception appears 
to be umbilical cord progenitor cells, which implies that other cells 
harvested from cord blood (i.e. earlier primitive stem cells that are 
not progenitors and non-haematopoietic stem cells) will also require 
ministerial authorisation. The legislator’s reason for making this 
distinction is not apparent. On the other hand, no mention is made of 
the requirement for ministerial approval in the Regulations Relating 
to the Use of Human Biological Material, which provide that biological 
material – which includes progenitor stem cells[6] – may be removed 
or withdrawn from living adult persons with their informed consent.[7] 
It is suggested that section 56(2)(a)(iv) above be changed to refer only 
to ‘embryonic or fetal tissue’. 
In addition to Chapter 8, several important areas are covered by 
Chapter 9 of the NHA which deals with ‘National Health Research 
and Information’. Section 71, for example, entitled ‘Research on 
or experimentation with human subjects’, states that all research 
conducted on minors (e.g. persons younger than 18 years) for 
non-therapeutic purposes requires ministerial authorisation 
(section 71(3)), whereas in the instance of research for therapeutic 
purposes, ministerial authorisation is apparently not required 
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(section 71(2)), but only the consent of the parent or guardian, 
or the relevant child if he or she is capable of understanding. The 
rationale behind the requirement for ministerial authorisation 
where research or experimentation is to be conducted on a minor 
for non-therapeutic purposes (not benefiting the specific minor), 
but not for therapeutic purposes, is unclear. The Minister may not 
authorise such research for non-therapeutic purposes involving a 
minor if, among others, the research poses a ‘significant risk’ to the 
health of the minor, or ‘some risk’, though there is the likelihood 
of ‘some benefit’ to the minor (section 71(3)(b)). Paradoxically, it 
would seem that ministerial authorisation for the latter would be 
important. The purpose of this is clearly to protect minors from 
unscrupulous research practices, but in the absence of a definition 
of what ‘significant risk’ or ‘some risk’ are, which differ from the 
requirements stated in the national ethics guidelines,[8] this adds 
more confusion.[9]
Table 2. Definitions from the National Health Act and Regulations thereto relating to tissues and organs
Name Definition Source Comment / proposal
tissue human tissue, and includes flesh, bone, 
a gland, an organ, skin, bone marrow 
or body fluid, but excludes blood or a 
gamete
National Health Act (No. 61 of 
2003)
Proposal – replace with:
human tissue, and includes skin and 
appendages, flesh, bone, bone marrow, body 
fluid, a gland, an organ, but excludes blood, 
gametes and stem cells
a functional group of cells. The term 
is used collectively in Regulations to 
indicate both cells and tissue 
Regulations Relating to Tissue 
Banks (No. R. 182)
organ any part of the human body adapted 
by its structure to perform any 
particular vital function, including the 
eye and its accessories, but does not 
include skin and appendages, flesh, 
bone, bone marrow, body fluid, blood 
or a gamete
National Health Act (No. 61 of 
2003)
Proposal – replace with:
any part of the human body adapted by 
its structure to perform any particular vital 
function, including the eye and its accessories, 
but does not include skin and appendages, 
flesh, bone, bone marrow, body fluid, blood, a 
gamete or stem cells
biological material material from a human being including 
DNA, RNA, blastomeres, polar bodies, 
cultured cells, embryos, gametes, 
progenitor stem cells, small tissue 
biopsies and growth factors from the 
same
Regulations Relating to the Use 
of Human Biological Material 
(No. R. 177)
biological samples no definition in the current legislation Proposal:
samples derived from tissue and blood 
including cells, DNA, RNA and protein
body specimen any body sample which can be tested 
to determine the presence or absence 
of HIV infection
Regulations regarding the 
Rendering of Clinical Forensic 
Medicine Services (No. R. 176)
body fluid any body substance which may contain 
HIV or any other sexually transmissible 
infection, but does not include saliva, 
tears or perspiration
Regulations regarding the 
Rendering of Clinical Forensic 
Medicine Services (No. R. 176)
substance tissue, blood, blood product or gamete Regulations Relating to the 
Import and Export of Human 
Tissue, Blood, Blood Products, 
Cultured Cells, Stem Cells, 
Embryos, Foetal Tissue, Zygotes 
and Gametes. (No. R. 181)
to traffic no definition in the current legislation Proposal:
to recruit, transport, transfer, harbour or 
receive tissue by means of threat, coercion, 
abduction, fraud, deception or the abuse of 
power of a position of vulnerability, or to give 
or receive payments or benefits to achieve the 
transfer of tissue
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Table 3. Definitions from the National Health Act and Regulations thereto relating to stem cells
Name Definition Source Comment /proposal
cell the basic structural and functional unit in people and 
all living things and is a small container of chemical 
and water wrapped in a membrane
Regulations Relating to the Artificial 
Fertilisation of Persons (No. R. 175)
This definition is not 
appropriate
the smallest structural and functional unit of an 
organism, consisting of cytoplasm and a nucleus 
enclosed in a membrane in living things
Regulations Relating to the Use of Human 
Biological Material
(No. R. 177)
cultured cells cells that have been grown outside the body Regulations Relating to the Use of Human 
Biological Material
(No. R. 177)
any human cells grown in vitro supported by suitable 
growth media
Regulations Relating to the Import and Export of 
Human Tissue, Blood, Blood Products, Cultured 
Cells, Stem Cells, Embryos, Foetal Tissue, Zygotes 
and Tametes
(No. R. 181)
stem cell a cell that has both the capacity to self-renew as well 
as to differentiate into mature, specialised cells
Regulations Relating to the Use of Human 
Biological Material
(No. R. 177)
a cell that has both the capacity to self-renew as well as 
to differentiate into mature, specialised cells
Regulations Relating to Blood and Blood 
Products
(No. R. 179)
any embryonic stem cell or circulating, bone marrow, 
umbilical cord or haemopoietic progenitor cell, or 
any cell that is capable of replicating or proliferating 
and giving rise to a differentiated cell
Regulations Relating to the Import and Export 
of Human Tissue, Blood, Blood Products, 
Cultured Cells, Stem Cells, Embryos, Foetal 
Tissue, Zygotes and Gametes
(No. R. 181)
cells that have both the capacity to self-regenerate as 
well as to differentiate into mature specialised cells














any cell from the 30-200 inner cell mass of the 
blastocyst










xenogeneic to replace 
“transgenic”
reproductive 
cloning of a 
human being
the manipulation of genetic material in order to 
achieve the reproduction of a human being and 
includes nuclear transfer or embryo splitting for such 
purpose
National Health Act
(No. 61 of 2003)
Section 57(6)(a)
Proposal – replace with:
the manipulation of 
cells, gametes, zygotes 
or embryos or genetic 
material derived 
therefrom in order to 
achieve the reproduction 
of a human being, 
and includes but is 
not limited to nuclear 
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Regulations 
Various sets of regulations relating to Chapter 8 of the NHA came 
into effect on 2 March 2012 (Table 4). These include regulations 
relating to the general control of human bodies, tissue, blood, 
blood products and gametes;[10] the use of human biological 
material;[11] blood and blood products;[12] import and export of 
human tissue,  blood, blood products, cultured cells, stem cells, 
embryos, fetal tissue, zygotes and gametes;[13] stem cell banks[14] 
and tissue banks.[15] With regard to some of these sets of regulations 
that relate to human tissue, there is a degree of redundancy 
and overlap. Definitions, for example, are not harmonised, both 
between different regulations and relative to the NHA. In addition, 
there are at present no regulations regarding cell-based therapy, 
bio-banks or transplantation.
With regard to definitions, a cell is defined in Regulations Relating 
to the Artificial Fertilisation of Persons as ‘the basic structural and 
functional unit in people and all living things and is a small container 
of chemical and water wrapped in a membrane’ (Table 3). This 
definition is clearly wanting for detail, which is necessary in the 
modern setting of highly sophisticated technology. On the other 
hand, the regulations on the use of human biological material defines 
a cell as ‘the smallest structural and functional unit of an organism, 
consisting of cytoplasm and a nucleus enclosed in a membrane in 
living things’, which is more appropriate.
Transgenic cells are defined in the Regulations Relating to the Use 
of Human Biological Material as cells being ‘derived from a species 
other than human’. The universally accepted definition of cells derived 
from a species other than human is ‘xenogeneic’. For example, 
one source[16] defines xenogeneic as ‘derived or obtained from an 
organism of a different species, as a tissue graft’.
Transgenic on the other hand means an organism whose genome 
has been altered by the transfer of a gene or genes through 
recombinant DNA techniques from another species or breed 
using recombinant DNA techniques, e.g. transgenic mice.[17] It is 
understood that the foreign genes are in the transgenic animal’s 
germ-cell DNA and so can be transmitted from one generation to 
the next.[18] 
Clearly this and other frankly incorrect definitions require urgent 
amendment.
Guidelines and standards
With regard to guidelines and standards, none have been officially 
published or endorsed by the National Department of Health in the 
human tissue field. As a result and in response to the need to provide 
clarity to professionals working in these fields, several professional 
bodies have established their own guidelines. These bodies are listed 
in Table 5.
It should be noted, however, that national standards for cellular 
therapy product collection, processing, storage and distribution 
have been drafted and will hopefully be published in the near future. 
These standards do not include stem cell therapy per se, which would 
for now need to be covered in SA by the South African Stem Cell 
Transplantation Society standards. It is important that the drafting 
of all guidelines and standards be done in close alignment with 
national professional bodies, as well as international bodies such as 
the Foundation for the Accreditation of Cellular Therapy,[19] the Joint 
Table 3. (continued) Definitions from the National Health Act and Regulations thereto relating to stem cells
Name Definition Source Comment /proposal
therapeutic 
cloning
the manipulation of genetic material from either 
adult, zygotic or embryonic cells in order to alter, for 
therapeutic purposes, the function of cells or tissues
National Health Act
(No. 61 of 2003)
Section 57(6)(b)
Definition should 
include somatic cell 
nuclear transfer – for 
example, replace with:
use of embryonic stem 
cells, which are derived 
from a blastocyst 
following somatic cell 
nuclear transfer, for 
therapeutic purposes
Table 4
Regulations published in Government Gazette No. 35099 on 2 March 2012
Regulation 
No. Title Pages
No. R. 175 Regulations Relating to Artificial Fertilisation of Persons GG 35099 pages 3-21
No. R. 176 Regulations Regarding the Rendering of Clinical Forensic Medicine Services GG 35099 pages 22-30
No. R. 177 Regulations Relating to the Use of Human Biological Material GG 35099 pages 31-38
No. R. 179 Regulations Relating to Blood and Blood Products GG 35099 pages 62-74
No. R. 180 Regulations Regarding the General Control of Human Bodies, Tissue, Blood, Blood Products and Gametes GG 35099 pages 75-96
No. R. 181 Regulations Relating to the Import and Export of Human Tissue, Blood, Blood Products, Cultured Cells, 
Stem Cells, Embryos, Foetal Tissue, Zygotes and Gametes. GG 35099 pages 97-124
No. R. 182 Regulations Relating to Tissue Banks GG 35099 pages 125-141
No. R. 183 Regulations Relating to Stem Cell Banks GG 35099 pages 142-158
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Accreditation Committee of the International Society for Cellular 
Therapy (ISCT) and the European Society for Blood and Marrow 
Transplantation (EBMT)[20] and the American Association of Blood 
Banks.[21] 
Economic considerations
Section 60 of the NHA, titled ‘Payment in connection with the 
importation, acquisition or supply of tissue, blood, blood products or 
gametes’ stipulates the following:
‘(1) No person, except- 
(a) a hospital or an institution contemplated in section 58(l)(a), a 
person or an institution contemplated in section 63 and an authorised 
institution or, in the case of tissue or gametes imported or exported in 
the manner provided for in the regulations, the importer or exporter 
concerned, may receive payment in respect of the acquisition, supply, 
importation or export of any tissue or gamete for or to another person 
for any of the purposes contemplated in section 56 or 64;
(b) a person or an institution contemplated in section 63 or an authorized 
institution, may receive any payment in respect of the importation, export 
or acquisition for the supply to another person of blood or a blood product.
(2) The amount of payment contemplated in subsection (1) may not 
exceed an amount which is reasonably required to cover the costs 
involved in the importation, export, acquisition or supply of the tissue, 
gamete, blood or blood product in question.
(3) This section does not prevent a health care provider registered with 
a statutory health professional council from receiving remuneration for 
any professional service rendered by him or her.
(4) It is an offence for a person-
(a) who has donated tissue, a gamete, blood or a blood product to receive 
any form of financial or other reward for such donation, except for the 
reimbursement of reasonable costs incurred by him or her to provide such 
donation; and
 (b) to sell or trade in tissue, gametes, blood or blood products, except as 
provided for in  this Chapter.
(5) Any person convicted of an offence in terms of subsection (4) is liable 
on conviction to a fine or to imprisonment for a period not exceeding five 
years or to both a fine and such imprisonment.’
Any discussion on human tissue legislation (and in particular 
stem cells) needs to make a distinction between activities that 
involve altruistic donation of human material and those that result 
in commercial gain. Any commercial activity directly involving 
human material (including stem cells) that is provided on an 
altruistic basis by a voluntary donor should be run on a not-for-
profit cost recovery basis with publicly accessible accountability of 
how resources are managed. Other activities that involve human 
stem cells directly or indirectly and that are not based on the 
principle of an altruistic donation should be permitted to run on 
a for-profit basis. This includes storage and manipulation of stem 
cells for individuals who pay for the service on a fee-for-service 
basis, as well as all related activities including but not limited to 
the development and manufacture of materials for tissue culture 
(equipment, plastic ware, reagents including growth factors) and 
medical devices (including those required for stem cell harvesting 
and purification). It is important to note that the NHA prohibits 
the sale of and trade in stem cells, as this would be tantamount to 
‘organ trafficking’ even though a stem cell(s) is not an organ per se. 
Furthermore, an authorised institution may only receive payment 
in respect of the acquisition, supply, importation or export of stem 
cells.
Although it is clear that a public cord-blood bank in which stem cells 
are altruistically donated must be a not-for-profit company run on the 
basis of cost-recovery, the indiscriminate application across the board 
of a not-for-profit rule in all matters pertaining to human tissues and 
stem cells, in particular, would severely stifle the rollout of stem cell 
therapies and related research in SA. The cell therapy industry is still 
in its infancy in this country, and preventing the establishment of 
for-profit companies would stifle the implementation of new cell 
therapy technologies as well as all future research activity into stem 
cells in the biotechnology sector. The latter is emphasised in the 
Bioeconomy strategy released in 2014 by the Department of Science 
and Technology.[22] The therapeutic promise of stem cells has driven 
huge investment globally into the cell therapy industry. Without 
this investment, and the return it promises to bring to its investors, 
progress in the field would be significantly stunted. 
Table 5. Professional Bodies: Human tissues
Area Professional body Guidelines
Transplantation Southern African Transplantation Society (SATS) Yes
http://www.sats.org.za/Guidelines.asp 
Assisted reproductive technology Southern African Society of Reproductive 





Blood and blood products National Blood Committee
(not in operation since 2008)
Yes
SANBS and WPBTS websites & other
Cell-based therapy South African Stem Cell Transplantation Society 
(SASCTS)
Yes; none on website
http://www.stemcell.org.za/index.htm 
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Conclusion
Legislation in its broadest sense should be seen as a permanent work-
in-progress requiring ongoing review. The importance of feedback 
from all sectors concerned including patients and their healthcare 
providers cannot be overemphasised. 
Legislation in its broadest sense is needed:
• To ensure that pre-clinical studies and well controlled clinical trials 
have been conducted prior to introduction of cells into patients:
• to ensure that the purported therapeutic effect is real 
• to ensure that there are no serious side effects
• To ensure that work involving material that will be (re)introduced 
into patients is conducted in an accredited institution under strictly 
controlled conditions.
The absence of appropriate legislation:
• Permits (and even encourages) the emergence of medically 
unsound and unethical practices that may be associated with the 
exploitation of emotionally vulnerable patients.
• Dissuades the transfer into SA of much-needed skilled individuals, 
intellectual property and foreign investment in the cell-therapy 
field.
In SA we have ‘need’ from the perspective of the patient, ‘ability’ from 
the perspective of the medical, scientific and business communities, 
and ‘material’ both from a research and therapeutic perspective. 
Legislation in SA in the human tissue field, and in stem cells in par-
ticular, is still in its infancy. This provides healthcare professionals and 
researchers with an opportunity to assist the legislator in drafting 
legislation that is both modern and appropriate to the diverse 
needs of the SA population. However, while legislation is necessary 
to protect patients and their healthcare providers, it should not be 
stifling or obstructive. 
With regard to clinical trials, these need to be registered with the 
Medicines Control Council (MCC) and would include any form of 
therapy that is unproven or experimental in nature. Protocols need 
to be examined by a registered institutional ethics committee (peer 
reviewed). Finally, patients should not have to pay for treatments that 
are unproven or experimental.
Based on the broad outline provided above and in mapping out the 
process ahead, it is recommended that: 
• An oversight and coordinating committee be established, which 
includes government, academia and the private sector, to work with 
groups in each of the seven areas delineated above together with 
the legislator, to constantly monitor new developments in order to 
be able to be agile in response thereto.
• The current legislation be revised to close regulatory gaps, remove 
inaccuracies and redundancy and to ensure that all legislation is 
harmonised.
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